Showing 1 - 3 results of 3 for search 'Pei-Hong Wu', query time: 0.03s Refine Results
  1. 1
    Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study

    Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C... by Tian-Qi Zhang, Zhi-Jun Geng, Meng-Xuan Zuo, Ji-Bin Li, Jin-Hua Huang, Zi-Lin Huang, Pei-Hong Wu, Yang-Kui Gu

    Published 2023-10-01
    Get full text
    Article
  2. 2
    Anomalous gray matter structural networks in patients with hepatitis B virus-related cirrhosis without overt hepatic encephalopathy.

    Anomalous gray matter structural networks in patients with hepatitis B virus-related cirrhosis without overt hepatic encephalopathy. by Xiao-Fei Lv, Kai Liu, Ying-Wei Qiu, Pei-Qiang Cai, Jing Li, Gui-Hua Jiang, Yan-Jia Deng, Xue-Lin Zhang, Pei-Hong Wu, Chuan-Miao Xie, Ge Wen

    Published 2015-01-01
    Get full text
    Article
  3. 3
    Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.

    Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. by Fang Zheng, Yi-Ji Liao, Mu-Yan Cai, Tian-Hao Liu, Shu-Peng Chen, Pei-Hong Wu, Long Wu, Xiu-Wu Bian, Xin-Yuan Guan, Yi-Xin Zeng, Yun-Fei Yuan, Hsiang-Fu Kung, Dan Xie

    Published 2015-02-01
    Get full text
    Article

Search Tools: